Reports Q4 revenue $66.95M, consensus $63.45M. Total orders received for Q4 grew to $71.1M. Total orders received for FY23 grew to $264M compared to $226.4M for FY22. “Fiscal 2023 was a defining year for Twist as we grew our revenue 20% year over year with strength in NGS and synbio in particular,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “We took decisive action to align our cost structure with our accelerated path to profitability and implemented our strategy for key products to set the stage for near and long-term success.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TWST:
- Options Volatility and Implied Earnings Moves Today, November 17, 2023
- Is TWST a Buy, Before Earnings?
- Twist Bioscience enters antibody discovery, license agreement with Bayer
- Becton, Medtronic, Twist, Zimmer added to ‘Tactical Outperform’ list at Evercore
- Twist Bioscience initiated with a Buy at Berenberg